SARS冠状病毒S蛋白RBD片段抗原多肽的合成及其多克隆抗体制备  

Synthesis the Polypeptide of SARS-CoV Spike Protein RBD (Receptor Binding Domain) and Production the Ployclonal Antibody

作　　者：徐德意[1] 肖洪广[1] 高俊[1] 

机构地区：[1]广州医学院第一附属医院检验系,广州510120

出　　处：《热带医学杂志》2010年第9期1062-1064,共3页Journal of Tropical Medicine

基　　金：广东省自然科学基金(No.06022094);广州市科技局应用基础项目(No.2004J1-C0211);广州市教委科研项目(No.1040;No.1047)

摘　　要：目的研究SARS冠状病毒spike蛋白的抗原优势表位,合成多肽免疫小鼠获得多克隆抗体。方法通过固相Fmoc法合成spike蛋白三条多肽CQ19、LV11、TY14,与KLH肽链结合,免疫小鼠。结果固相多肽合成法合成KLH-CQ19、KLH-LV11和KLH-TY14三条多肽,用KLH-CQ19多肽片段免疫小鼠获得多克隆抗体。结论 KLH-CQ19片段免疫小鼠获得有效多克隆抗体,为SARS的抗体后续研究提供了物质基础。Objective To study the best epitope of SARS-CoV spike protein, and to raise the polyclonal antibody.Methods Polypeptide CQ19, LV11 and TY14 were synthezed by Fmoc technique, and were then used to immunize BABL/c mice.Results KLH-CQ19, KLH-LV11 and KLH-TY14 polypeptide were constructed.Polyclonal antibodies against these polypeptide were raised from BALB/c mice.Conclusion The receptor binding domain （RBD） of SARS-CoV spike protein was analyzed by computer to predict the potential epitopes.Polypeptides of these epitopes were synthezed and polyclonal antibodies against these epitopes were raised from BABL/c mice.These polyclonal antibodies can be used for the further study on the clinical application of SARS.

关 键 词：SARS冠状病毒 SPIKE蛋白 RBD 抗体 

分 类 号：R392.11[医药卫生—免疫学]